摘要
目的 研究烫伤脓毒症大鼠肾脏核转录因子-κB(NF-κB)活化与肾损伤的关系。方法 采用 30％总体表面积Ⅲ度烫伤加内毒素攻击制备烫伤脓毒症大鼠模型。54只Wistar大鼠随机分为正常对照组、 烫伤脓毒症1、2、6、12和24 h组,烫伤脓毒症1、2和6 h+NF-κB抑制剂吡咯烷二硫基甲酸酯(PDTC)组。采 用凝胶电泳迁移率改变分析法(EMSA)检测肾组织NF-κB活性;采用酶联免疫吸附法检测血浆及肾组织中 肿瘤坏死因子-α(TNF-α)含量的变化;采用自动生化分析仪检测血肌酐(SCr)和尿素氮(BUN)含量。结果 肾组织NF-κB活性于烫伤脓毒症后1 h明显增强并达到高峰(P<0．01),PDTC可显著降低烫伤脓毒症后 1 h NF-κB的活性。烫伤脓毒症后1 h和2 h血浆及肾组织中TNF-α水平均明显增高(P均<0．01),PDTC 可显著降低伤后血浆TNF-α水平(P均<0．01),对肾组织中TNF-α水平影响不明显。烫伤脓毒症后BUN 及SCr含量均明显增高(P均<0．01),PDTC对BUN和SCr含量均无显著影响。结论 NF-κB抑制剂可降 低烫伤脓毒症大鼠肾组织NF-κB活性,但对肾脏功能无明显保护作用。
Objective To investigate the relationship between nuclear factor- kB （NF-kB） activity and kidney injury in rats with postburn sepsis. Methods Rats subjected to 30% full-thickness scald injury, followed by intraperitoneal injection of lipopolysaccharide（LPS）,were used in the present study. Fifty-four Wistar rats were randomly divided into normal control group, postburn sepsis 1, 2, 6, 12, 24 hours groups, and sepsis with NF-kB inhibitor pyrrolidine dithiocarbamate （PDTC） treatment 1, 2, and 6 hour groups. NF-kB activity, tumor necrosis factor-α（TNF-α） protein expression, and renal function were determined with electrophoretic mobility shift assay （EMSA）, enzyme linked immunoadsorbent assay （ELISA）, and automatic biochemistry analyzer, respectively. Results NF-kB activity in kidney was markedly enhanced and reached its peak 1 hour after scalding and injection of LPS （all P〈0.01）, and was decreased remarkally after the administration of PDTC. PDTC could suppress the elevated plasma TNF-α protein expression （both P〈0.01）, but not renal TNF -α levels. PDTC could not reduce blood urea nitrogen and blood creatinine contents, which were increased after scalding followed by LPS challenge. Conclusion The results suggest that the treatment with NF-kB inhibitor PDTC could down-regulate the NF-kB activity in kidney, but it could not protect the renal function in rats with postburn sepsis.
出处
《中国危重病急救医学》
CAS
CSCD
北大核心
2005年第12期722-725,共4页
Chinese Critical Care Medicine
基金
国家重点基础研究发展规划项目(2005CB522602
G1999054203-2)首都医学发展科研基金重点项目(2003-2023)
